Ippei Ikushima

416 total citations
19 papers, 325 citations indexed

About

Ippei Ikushima is a scholar working on Cardiology and Cardiovascular Medicine, Pharmacology and Surgery. According to data from OpenAlex, Ippei Ikushima has authored 19 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 5 papers in Pharmacology and 4 papers in Surgery. Recurrent topics in Ippei Ikushima's work include Atrial Fibrillation Management and Outcomes (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Cardiac Arrhythmias and Treatments (3 papers). Ippei Ikushima is often cited by papers focused on Atrial Fibrillation Management and Outcomes (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Cardiac Arrhythmias and Treatments (3 papers). Ippei Ikushima collaborates with scholars based in Japan, Germany and United States. Ippei Ikushima's co-authors include Makoto Takenaga, Yasushi Koiwaya, Takuroh Imamura, Haruhiko Date, Yoshitatsu Nagatomo, Tadashi Ishikawa, Kazuo Kitamura, Tanenao Eto, Akiko Harada and Shin Irie and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and American Heart Journal.

In The Last Decade

Ippei Ikushima

18 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ippei Ikushima Japan 9 160 143 103 69 59 19 325
Srinivasan Sattiraju United States 8 262 1.6× 41 0.3× 426 4.1× 12 0.2× 60 1.0× 36 588
Jens‐Otto Andreas Germany 11 38 0.2× 40 0.3× 35 0.3× 32 0.5× 20 0.3× 18 458
Tom Bäcklund Finland 9 91 0.6× 81 0.6× 75 0.7× 33 0.5× 22 0.4× 16 373
Robert David United States 13 192 1.2× 18 0.1× 50 0.5× 12 0.2× 21 0.4× 18 686
Pietari Kinnunen Finland 7 213 1.3× 213 1.5× 90 0.9× 49 0.7× 66 1.1× 9 357
Maciej P. Golan Poland 10 92 0.6× 32 0.2× 26 0.3× 10 0.1× 64 1.1× 18 320
Gareth Matthews United Kingdom 11 136 0.8× 36 0.3× 226 2.2× 12 0.2× 26 0.4× 33 339
Jun Kishihara Japan 10 54 0.3× 23 0.2× 277 2.7× 16 0.2× 24 0.4× 58 355
Jack Young Canada 8 106 0.7× 39 0.3× 96 0.9× 52 0.8× 50 0.8× 18 303
Baopeng Tang China 9 28 0.2× 12 0.1× 171 1.7× 33 0.5× 31 0.5× 29 230

Countries citing papers authored by Ippei Ikushima

Since Specialization
Citations

This map shows the geographic impact of Ippei Ikushima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ippei Ikushima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ippei Ikushima more than expected).

Fields of papers citing papers by Ippei Ikushima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ippei Ikushima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ippei Ikushima. The network helps show where Ippei Ikushima may publish in the future.

Co-authorship network of co-authors of Ippei Ikushima

This figure shows the co-authorship network connecting the top 25 collaborators of Ippei Ikushima. A scholar is included among the top collaborators of Ippei Ikushima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ippei Ikushima. Ippei Ikushima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
3.
Totsuka, Kyoichi, et al.. (2019). Pharmacokinetic study of lascufloxacin in non-elderly healthy men and elderly men. Journal of Infection and Chemotherapy. 26(3). 231–239. 6 indexed citations
4.
Ikushima, Ippei, Lene Jensen, Anne Flint, et al.. (2018). A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Advances in Therapy. 35(4). 531–544. 23 indexed citations
5.
Ochiai, Ryoichi, et al.. (2018). Effect of chlorogenic acids on fatigue and sleep in healthy males: A randomized, double‐blind, placebo‐controlled, crossover study. Food Science & Nutrition. 6(8). 2530–2536. 11 indexed citations
6.
Yasaka, Masahiro, Ippei Ikushima, Akiko Harada, et al.. (2017). Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. Research and Practice in Thrombosis and Haemostasis. 1(2). 202–215. 13 indexed citations
7.
Shinozawa, Tadahiro, Koki Nakamura, Masanobu Shoji, et al.. (2017). Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes. Stem Cell Reports. 8(2). 226–234. 40 indexed citations
8.
Norris, Stephen H., Steven Ramael, Ippei Ikushima, et al.. (2017). Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. British Journal of Clinical Pharmacology. 83(8). 1815–1825. 9 indexed citations
9.
10.
Schmohl, Michael, Stephan Glund, Akiko Harada, et al.. (2016). Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thrombosis and Haemostasis. 117(2). 269–276. 23 indexed citations
11.
Ryn, Joanne van, Masahiro Yasaka, Ippei Ikushima, et al.. (2016). Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers. Blood. 128(22). 2627–2627. 4 indexed citations
12.
Ryn, Joanne van, Stephen H. Norris, Steven Ramael, et al.. (2016). EVALUATION OF THE IMMUNOGENICITY OF THE DABIGATRAN REVERSAL AGENT IDARUCIZUMAB: POOLED ANALYSIS OF PHASE I DATA. Journal of the American College of Cardiology. 67(13). 2289–2289. 3 indexed citations
13.
Fujimori, Shunji, et al.. (2015). Celecoxib Monotherapy Maintained Small Intestinal Mucosa Better Compared With Loxoprofen Plus Lansoprazole Treatment. Journal of Clinical Gastroenterology. 50(3). 218–226. 13 indexed citations
14.
Haahr, Hanne, et al.. (2015). Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects. Journal of Diabetes Investigation. 7(4). 574–580. 7 indexed citations
15.
16.
Shiramoto, Masanari, Yoshikazu Kaji, Kyoko Matsuguma, et al.. (2013). Evaluation of Assay Sensitivity and the Concentration-Effect Relationship of Moxifloxacin in a QT/QTc Study in Japan. Therapeutic Innovation & Regulatory Science. 48(2). 181–189. 1 indexed citations
17.
Kashio, Nobuyuki, et al.. (2003). Serum Lipoprotein(a) Concentration and Apo(a) Isoform under The Condition of Renal Dysfunction. Journal of Atherosclerosis and Thrombosis. 10(5). 283–289. 10 indexed citations
18.
Takenaga, Makoto, et al.. (1998). Magnetic Resonance Imaging of Bland-White-Garland Syndrome. Japanese Circulation Journal. 62(3). 219–221. 6 indexed citations
19.
Kitamura, Kazuo, Haruhiko Date, Ippei Ikushima, et al.. (1996). Increased plasma adrenomedullin in acute myocardial infarction. American Heart Journal. 131(4). 676–680. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Srinivasan Sattiraju Breakdown of academic impact, for papers by Jens‐Otto Andreas Breakdown of academic impact, for papers by Tom Bäcklund Breakdown of academic impact, for papers by Robert David Breakdown of academic impact, for papers by Pietari Kinnunen Breakdown of academic impact, for papers by Maciej P. Golan Breakdown of academic impact, for papers by Gareth Matthews Breakdown of academic impact, for papers by Jun Kishihara Breakdown of academic impact, for papers by Jack Young Breakdown of academic impact, for papers by Baopeng Tang
Rankless by CCL
2026